At #KidneyWk 2025, onconephrology innovations took center stage with many oral presentations showcasing updates, therapies, and mechanisms. Read about the field's progress in #ASNKidneyNews: kidney.pub/KN1801-12
February 2, 2026 at 3:02 PM
At #KidneyWk 2025, onconephrology innovations took center stage with many oral presentations showcasing updates, therapies, and mechanisms. Read about the field's progress in #ASNKidneyNews: kidney.pub/KN1801-12
#KidneyWk used to be a highlight of my year and I was really proud to support @asnkidney.bsky.social .
Its tacit acceptance of Donald Trump and his actions has been a major disappointment for me.
So, yes …👇
Its tacit acceptance of Donald Trump and his actions has been a major disappointment for me.
So, yes …👇
January 30, 2026 at 5:33 PM
#KidneyWk used to be a highlight of my year and I was really proud to support @asnkidney.bsky.social .
Its tacit acceptance of Donald Trump and his actions has been a major disappointment for me.
So, yes …👇
Its tacit acceptance of Donald Trump and his actions has been a major disappointment for me.
So, yes …👇
Nice @kidneyboy.bsky.social
Love the frigid run
I might be able to keep up with you, maybe run together at #KidneyWk later this year?
Love the frigid run
I might be able to keep up with you, maybe run together at #KidneyWk later this year?
January 25, 2026 at 1:45 AM
Nice @kidneyboy.bsky.social
Love the frigid run
I might be able to keep up with you, maybe run together at #KidneyWk later this year?
Love the frigid run
I might be able to keep up with you, maybe run together at #KidneyWk later this year?
Conservative kidney management (CKM), is an active, patient-centered approach to managing advanced kidney failure without dialysis, has a growing base of evidence, and was featured at #KidneyWk 2025. Read more in #ASNKidneyNews: kidney.pub/KN1801-15
January 13, 2026 at 3:01 PM
Conservative kidney management (CKM), is an active, patient-centered approach to managing advanced kidney failure without dialysis, has a growing base of evidence, and was featured at #KidneyWk 2025. Read more in #ASNKidneyNews: kidney.pub/KN1801-15
Far more patients with kidney disease are eligible for home-dialysis compared to those who engage in it. A recent panel at #KidneyWk 2025 says education is critical to adopting the technology: kidney.pub/KN1801-03 #ASNKidneyNews
January 12, 2026 at 3:00 PM
Far more patients with kidney disease are eligible for home-dialysis compared to those who engage in it. A recent panel at #KidneyWk 2025 says education is critical to adopting the technology: kidney.pub/KN1801-03 #ASNKidneyNews
At #KidneyWk 2025, four people with kidney disease discussed how dietary changes helped keep their conditions in check. Now, they're working on a kidney cookbook. Read more about their experiences in #ASNKidneyNews: kidney.pub/KN1801-23
January 10, 2026 at 3:00 PM
At #KidneyWk 2025, four people with kidney disease discussed how dietary changes helped keep their conditions in check. Now, they're working on a kidney cookbook. Read more about their experiences in #ASNKidneyNews: kidney.pub/KN1801-23
At #KidneyWk 2025, Rebecca Schmidt presented multifaceted strategies to expand kidney care to rural areas. Read #ASNKidneyNews coverage of the presentation here: kidney.pub/KN1712-18
December 31, 2025 at 5:00 PM
At #KidneyWk 2025, Rebecca Schmidt presented multifaceted strategies to expand kidney care to rural areas. Read #ASNKidneyNews coverage of the presentation here: kidney.pub/KN1712-18
In a session at #KidneyWk, speakers highlighted how innovations have improved CKD care, and also advanced health equity. Read more in #ASNKidneyNews: kidney.pub/KN1712-17
December 30, 2025 at 5:00 PM
In a session at #KidneyWk, speakers highlighted how innovations have improved CKD care, and also advanced health equity. Read more in #ASNKidneyNews: kidney.pub/KN1712-17
Pediatric results from DUPLEX show sparsentan is well tolerated and achieves superior, sustained proteinuria reduction versus the maximum IRB dose in FSGS. #KidneyWk #nephsky #Nephrology #FSGS #Pediatrics www.docwirenews.com/post/sparsen...
Sparsentan Safe and Effective for Pediatric Patients With FSGS | Docwire News
A subanalysis of DUPLEX study data showed sparsentan resulted in proteinuria reduction for pediatric patients with focal segmental glomerulosclerosis (FSGS).
www.docwirenews.com
December 29, 2025 at 5:15 PM
Pediatric results from DUPLEX show sparsentan is well tolerated and achieves superior, sustained proteinuria reduction versus the maximum IRB dose in FSGS. #KidneyWk #nephsky #Nephrology #FSGS #Pediatrics www.docwirenews.com/post/sparsen...
What role do CD38+ immune cells play in AMR and glomerular disease? Georg Böhmig, MD, shares insights from #KidneyWk and what’s next for CD38-targeted therapies. #nephrology #nephsky #kidneytransplantation #kidneydisease www.docwirenews.com/post/targeti...
Targeting CD38+ Cells | Docwire News
Georg Böhmig, MD, discussed the role of CD38+ cells in immune-mediated kidney disease and felzartamab as a treatment for antibody-mediated rejection in kidney transplantation.
www.docwirenews.com
December 26, 2025 at 5:02 PM
What role do CD38+ immune cells play in AMR and glomerular disease? Georg Böhmig, MD, shares insights from #KidneyWk and what’s next for CD38-targeted therapies. #nephrology #nephsky #kidneytransplantation #kidneydisease www.docwirenews.com/post/targeti...
ICYMI: RUBY-3 demonstrates that targeting BAFF and APRIL with povetacicept can drive proteinuria reduction and immunologic remission in IgAN and pMN. #KidneyWk #nephsky #Nephrology #ClinicalTrials www.docwirenews.com/post/povetac...
Povetacicept Shows Disease-Modifying Potential in IgAN and Primary MN | Docwire News
Povetacicept showed sustained proteinuria reduction and stable glomerular filtration rate at 48 weeks for patients with IgA nephropathy and primary membranous nephropathy.
www.docwirenews.com
December 23, 2025 at 8:03 PM
ICYMI: RUBY-3 demonstrates that targeting BAFF and APRIL with povetacicept can drive proteinuria reduction and immunologic remission in IgAN and pMN. #KidneyWk #nephsky #Nephrology #ClinicalTrials www.docwirenews.com/post/povetac...
SPRINT data show intensive BP control favors most CKD patients, with greatest net benefit in those with lower eGFR. #KidneyWk #nephrology #CKD #hypertension #nephsky www.docwirenews.com/post/intensi...
Intensive BP Lowering Offers Benefit to Patients With CKD | Docwire News
Most patients with hypertension and chronic kidney disease (CKD) benefited from intensive BP lowering, especially those with more advanced CKD, an analysis of SPRINT data showed.
www.docwirenews.com
December 22, 2025 at 7:45 PM
SPRINT data show intensive BP control favors most CKD patients, with greatest net benefit in those with lower eGFR. #KidneyWk #nephrology #CKD #hypertension #nephsky www.docwirenews.com/post/intensi...
ICYMI: 12-month VISIONARY results show sibeprenlimab sustains proteinuria reduction and remission in IgA nephropathy. #KidneyWk #nephrology #IgAN #kidneydisease #nephsky www.docwirenews.com/post/protein...
Proteinuria Reduction in IgAN With Sibeprenlimab Sustained at 12 Months | Docwire News
An interim analysis of VISIONARY data showed that sibeprenlimab sustains reductions in proteinuria and key disease biomarkers in patients with IgA nephropathy (IgAN) at 12 months.
www.docwirenews.com
December 19, 2025 at 5:15 PM
ICYMI: 12-month VISIONARY results show sibeprenlimab sustains proteinuria reduction and remission in IgA nephropathy. #KidneyWk #nephrology #IgAN #kidneydisease #nephsky www.docwirenews.com/post/protein...
⏳ Final hours to claim your CME, CNE, CPE credits and MOC points from #KidneyWk 2025. Submit evaluations and share feedback for this year’s Early Programs and Annual Meeting sessions by 11:59 p.m. EST.
Log in to the ASN eLearning Center now. 👉 http://asn.kdny.info/gA2650XHQue
Log in to the ASN eLearning Center now. 👉 http://asn.kdny.info/gA2650XHQue
December 17, 2025 at 3:01 PM
⏳ Final hours to claim your CME, CNE, CPE credits and MOC points from #KidneyWk 2025. Submit evaluations and share feedback for this year’s Early Programs and Annual Meeting sessions by 11:59 p.m. EST.
Log in to the ASN eLearning Center now. 👉 http://asn.kdny.info/gA2650XHQue
Log in to the ASN eLearning Center now. 👉 http://asn.kdny.info/gA2650XHQue
ICYMI: Joel Topf @kidneyboy.bsky.social spoke with Vesna Garovic of Mayo Clinic at #KidneyWk about pregnancy and hypertension, the topic of Dr. Garovic's inaugural Sharon Silbiger, MD, Endowed Lecture. #nephsky #nephrology #hyptertension #pregnancy www.docwirenews.com/post/hyperte...
Hypertension and Pregnancy | Docwire News
Joel Topf, MD, and Vesna Garovic, MD, PhD, discussed pregnancy and hypertension, the topic of her inaugural Sharon Silbiger, MD, Endowed Lecture at ASN Kidney Week 2025.
www.docwirenews.com
December 15, 2025 at 5:15 PM
ICYMI: Joel Topf @kidneyboy.bsky.social spoke with Vesna Garovic of Mayo Clinic at #KidneyWk about pregnancy and hypertension, the topic of Dr. Garovic's inaugural Sharon Silbiger, MD, Endowed Lecture. #nephsky #nephrology #hyptertension #pregnancy www.docwirenews.com/post/hyperte...
The world’s premier nephrology meeting is on demand. Kidney Week On-Demand™ features 250+ hours of sessions from #KidneyWk 2025, covering science, clinical care, and innovation.
Want more? Seven Early Programs are also available separately for deep-dive education.
http://asn.kdny.info/2YBI50XHPJZ
Want more? Seven Early Programs are also available separately for deep-dive education.
http://asn.kdny.info/2YBI50XHPJZ
December 15, 2025 at 4:01 PM
The world’s premier nephrology meeting is on demand. Kidney Week On-Demand™ features 250+ hours of sessions from #KidneyWk 2025, covering science, clinical care, and innovation.
Want more? Seven Early Programs are also available separately for deep-dive education.
http://asn.kdny.info/2YBI50XHPJZ
Want more? Seven Early Programs are also available separately for deep-dive education.
http://asn.kdny.info/2YBI50XHPJZ
Don't miss our Kidney Week coverage, including research news and interviews with researchers and presenters. #nephrology #kidneywk #nephsky www.docwirenews.com/conference/a...
ASN Kidney Week 2025 | Docwire News
Review highlights from abstracts and presentations at ASN Kidney Week 2025, presented by the American Society of Nephrology, on Nephrology Times
www.docwirenews.com
December 14, 2025 at 6:15 PM
Don't miss our Kidney Week coverage, including research news and interviews with researchers and presenters. #nephrology #kidneywk #nephsky www.docwirenews.com/conference/a...
Did you miss the ASN Presidential Address at #KidneyWk? Read the address in #ASNKidneyNews, featuring a discussion of momentum and challenges in the fight for a cure to kidney diseases: kidney.pub/KN1712-05
December 12, 2025 at 6:00 PM
Did you miss the ASN Presidential Address at #KidneyWk? Read the address in #ASNKidneyNews, featuring a discussion of momentum and challenges in the fight for a cure to kidney diseases: kidney.pub/KN1712-05
11/10
Up next 12/16/25 we’re talking about AKI and best strategies for renal recovery from dialysis #nephjc
LIBERATE-D, simultaneous @jama.com publication during #KidneyWk pubmed.ncbi.nlm.nih.gov/41201895/
Up next 12/16/25 we’re talking about AKI and best strategies for renal recovery from dialysis #nephjc
LIBERATE-D, simultaneous @jama.com publication during #KidneyWk pubmed.ncbi.nlm.nih.gov/41201895/
A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial - PubMed
ClinicalTrials.gov Identifier: NCT04218370.
pubmed.ncbi.nlm.nih.gov
December 12, 2025 at 2:59 PM
11/10
Up next 12/16/25 we’re talking about AKI and best strategies for renal recovery from dialysis #nephjc
LIBERATE-D, simultaneous @jama.com publication during #KidneyWk pubmed.ncbi.nlm.nih.gov/41201895/
Up next 12/16/25 we’re talking about AKI and best strategies for renal recovery from dialysis #nephjc
LIBERATE-D, simultaneous @jama.com publication during #KidneyWk pubmed.ncbi.nlm.nih.gov/41201895/
WATCH Matthew Weir, MD, discussing results from the phase 2 Explore-CKD trial of lorundrostat presented at #KidneyWk. #nephrology #nephsky #kidneydisease #CKD #hypertension
www.docwirenews.com/post/lorundr...
www.docwirenews.com/post/lorundr...
Lorundrostat and Aldosterone Synthase Inhibition for Hypertension | Docwire News
Matthew Weir discussed research from ASN Kidney Week showing lorundrostat reduced systolic BP and albuminuria and had benefits for chronic kidney disease (CKD) and hypertension.
www.docwirenews.com
December 11, 2025 at 10:38 PM
WATCH Matthew Weir, MD, discussing results from the phase 2 Explore-CKD trial of lorundrostat presented at #KidneyWk. #nephrology #nephsky #kidneydisease #CKD #hypertension
www.docwirenews.com/post/lorundr...
www.docwirenews.com/post/lorundr...
One week left! Don’t miss your chance to claim continuing education credits and MOC points.
If you attended #KidneyWk, be sure to:
✅ Complete evaluations
✅ Share your feedback
✅ Claim CME, CNE, and CPE credits, and MOC points
📅Deadline: Wednesday, December 17
🔗 http://asn.kdny.info/Ni8Y50XFMxt
If you attended #KidneyWk, be sure to:
✅ Complete evaluations
✅ Share your feedback
✅ Claim CME, CNE, and CPE credits, and MOC points
📅Deadline: Wednesday, December 17
🔗 http://asn.kdny.info/Ni8Y50XFMxt
December 10, 2025 at 7:00 PM
One week left! Don’t miss your chance to claim continuing education credits and MOC points.
If you attended #KidneyWk, be sure to:
✅ Complete evaluations
✅ Share your feedback
✅ Claim CME, CNE, and CPE credits, and MOC points
📅Deadline: Wednesday, December 17
🔗 http://asn.kdny.info/Ni8Y50XFMxt
If you attended #KidneyWk, be sure to:
✅ Complete evaluations
✅ Share your feedback
✅ Claim CME, CNE, and CPE credits, and MOC points
📅Deadline: Wednesday, December 17
🔗 http://asn.kdny.info/Ni8Y50XFMxt
Therapies for IgA nephropathy and lupus took center stage in the High-Impact Trials sessions at ASN Kidney Week 2025. Read about a trio of therapies presented in #ASNKidneyNews: kidney.pub/KN1712-02 #KidneyWk
December 9, 2025 at 4:00 PM
Therapies for IgA nephropathy and lupus took center stage in the High-Impact Trials sessions at ASN Kidney Week 2025. Read about a trio of therapies presented in #ASNKidneyNews: kidney.pub/KN1712-02 #KidneyWk
Dr. Carla Nester discussed 52-week data on pegcetacoplan for #C3G demonstrating sustained proteinuria reduction (and remission in a third of patients). #nephrology #nephsky #glomerulardisease #kidneywk www.docwirenews.com/post/52-week...
52-Week Data Show Sustained Benefits of Pegcetacoplan in C3G | Docwire News
Dr. Carla Nester discussed VALIANT 52-week data presented at ASN Kidney Week 2025 showing sustained proteinuria reduction with pegcetacoplan in complement 3 glomerulopathy (C3G).
www.docwirenews.com
December 5, 2025 at 3:01 PM
Dr. Carla Nester discussed 52-week data on pegcetacoplan for #C3G demonstrating sustained proteinuria reduction (and remission in a third of patients). #nephrology #nephsky #glomerulardisease #kidneywk www.docwirenews.com/post/52-week...
Check out the December issue of KDIGO Direct: kdigo.co/KDIGO-Direct...
In this issue:
- Controversies Conference on Tech in Guideline-Informed Care
- KDIGO convenes Executive Committee
- KDIGO at ASN #KidneyWk
- New KDIGO #APOL1 and #IgAN podcast episodes!
- Upcoming activities & new resources
In this issue:
- Controversies Conference on Tech in Guideline-Informed Care
- KDIGO convenes Executive Committee
- KDIGO at ASN #KidneyWk
- New KDIGO #APOL1 and #IgAN podcast episodes!
- Upcoming activities & new resources
December 4, 2025 at 6:38 PM
Check out the December issue of KDIGO Direct: kdigo.co/KDIGO-Direct...
In this issue:
- Controversies Conference on Tech in Guideline-Informed Care
- KDIGO convenes Executive Committee
- KDIGO at ASN #KidneyWk
- New KDIGO #APOL1 and #IgAN podcast episodes!
- Upcoming activities & new resources
In this issue:
- Controversies Conference on Tech in Guideline-Informed Care
- KDIGO convenes Executive Committee
- KDIGO at ASN #KidneyWk
- New KDIGO #APOL1 and #IgAN podcast episodes!
- Upcoming activities & new resources